| Grant ID | CP120017 |
| Awarded On | March 29, 2012 |
| Title | Clinically Actionable Mutation Profiling for Cancer Personalized Medicine using Scalable, Ultra-deep Next Generation Sequencing |
| Program | Product Development Research |
| Award Mechanism | Company Commercialization |
| Institution/Organization | Asuragen, Inc. |
| Principal Investigator/Program Director | Gary Latham |
| Cancer Sites | All Sites |
| Contracted Amount | $6,837,265 |
| Lay Summary |
We propose to establish targeted next generation sequencing (NGS) assays that enable accurate, sensitive, and cost-effective detection of “actionable” mutations in clinically relevant, cancer-related genes. The existing armament of anticancer drugs includes ~100 approved therapies, and an additional 800 drugs in development. The NGS assays will interrogate mutations in key cancer pathways relevant to these medicines, and both improve the diagnostic yield of “real world” clinical biopsies and help steer drugs to those patients that are most likely to benefit. The funding for this proposal will help bridge the gap between the identified clinical utility of mutations and the need for clinical ... |